Founded in 2022, Moonlight AI develops AI-based diagnostics software that detects genomic biomarkers and complex disease signatures from routine blood and cytology smear images. Its technology integrates with existing laboratory imaging hardware to triage molecular testing, aiming to speed turnaround times and automate workflows. The company says this approach addresses bottlenecks in precision oncology caused by the cost and turnaround time of Next-Generation Sequencing. Moonlight is curating a proprietary dataset linking whole slide imaging with genomic data through an international clinical consortium to support model robustness across real-world settings. With the new seed funding, it plans to expand its data library and team, advance diagnostic solutions for MDS, NSCLC and CLL, and pursue commercialisation and regulatory approval. The company has transitioned into a Swiss Stock Corporation to support international expansion and commercial rollout.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

May 2026